Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

60 Degrees Pharmaceuticals (SXTPW) Net Margin (2022 - 2025)

Historic Net Margin for 60 Degrees Pharmaceuticals (SXTPW) over the last 4 years, with Q3 2025 value amounting to 529.48%.

  • 60 Degrees Pharmaceuticals' Net Margin rose 11498000.0% to 529.48% in Q3 2025 from the same period last year, while for Sep 2025 it was 872.75%, marking a year-over-year increase of 8212500.0%. This contributed to the annual value of 1387.57% for FY2024, which is 1601400.0% up from last year.
  • 60 Degrees Pharmaceuticals' Net Margin amounted to 529.48% in Q3 2025, which was up 11498000.0% from 1718.91% recorded in Q2 2025.
  • Over the past 5 years, 60 Degrees Pharmaceuticals' Net Margin peaked at 7992.11% during Q3 2023, and registered a low of 15148.79% during Q1 2023.
  • In the last 4 years, 60 Degrees Pharmaceuticals' Net Margin had a median value of 1439.25% in 2025 and averaged 1769.68%.
  • The largest annual percentage gain for 60 Degrees Pharmaceuticals' Net Margin in the last 5 years was 154409100bps (2024), contrasted with its biggest fall of -96713900bps (2024).
  • 60 Degrees Pharmaceuticals' Net Margin (Quarter) stood at 4457.05% in 2022, then crashed by -137bps to 1652.82% in 2023, then soared by 45bps to 902.08% in 2024, then soared by 41bps to 529.48% in 2025.
  • Its Net Margin was 529.48% in Q3 2025, compared to 1718.91% in Q2 2025 and 1225.67% in Q1 2025.